Merus NV to Discuss the Zeno Clinical Data and Provide a Program Update - Corporate Call Transcript
Good day and thank you for standing by. Welcome to the Merus Investor Call.
(Operator Instructions) Thank you. And I would like to hand the conference over to your first speaker for today, Kathleen Farren. Thank you.
Please go ahead, ma'am.
Good evening, everyone, and thank you for joining the Merus investor call to discuss our recently presented clinical data on zenocutuzumab or Zeno in NRG1 fusion cancers.
The slides we are presenting today are also available on the Investors & Media page of our website, www.merus.nl.
Before we get started on the call. We need to make some -- we will also be making certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about our future expectations and plans and events and circumstances that have not yet occurred, including but not limited to projections about Merus'
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |